Yu-Waye Chu - 19 Jul 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role: Chief Medical Officer
Signature: /s/ Lloyd Rowland, as Attorney-in-Fact for Yu-Waye Chu
Issuer symbol: CTMX
Transactions as of: 19 Jul 2023
Net transactions value: $0
Form type: 4
Filing time: 20 Jul 2023, 17:18:02 UTC
Previous filing: 19 Apr 2023
Next filing: 19 Jan 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTMX	Stock Option (Right to Buy)	Award	$0	+375,000		$0.000000	375,000	19 Jul 2023	Common Stock	375,000	$1.82	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to the option vest on the one year anniversary measured from July 19, 2023 (the "Vesting Commencement Date"), and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Content

25% of the shares subject to the option vest on the one year anniversary measured from July 19, 2023 (the "Vesting Commencement Date"), and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.